NO963837D0 - Nye muteiner av IFN- - Google Patents
Nye muteiner av IFN-Info
- Publication number
- NO963837D0 NO963837D0 NO963837A NO963837A NO963837D0 NO 963837 D0 NO963837 D0 NO 963837D0 NO 963837 A NO963837 A NO 963837A NO 963837 A NO963837 A NO 963837A NO 963837 D0 NO963837 D0 NO 963837D0
- Authority
- NO
- Norway
- Prior art keywords
- ifn
- beta
- those
- muteins
- recombinant dna
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Amplifiers (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/213,448 US5545723A (en) | 1994-03-15 | 1994-03-15 | Muteins of IFN-β |
PCT/US1995/003206 WO1995025170A1 (en) | 1994-03-15 | 1995-03-13 | NOVEL MUTEINS OF IFN-$g(b) |
Publications (3)
Publication Number | Publication Date |
---|---|
NO963837D0 true NO963837D0 (no) | 1996-09-13 |
NO963837L NO963837L (no) | 1996-11-14 |
NO318989B1 NO318989B1 (no) | 2005-05-30 |
Family
ID=22795174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19963837A NO318989B1 (no) | 1994-03-15 | 1996-09-13 | Nye muteiner av IFN-beta |
Country Status (12)
Country | Link |
---|---|
US (2) | US5545723A (no) |
EP (1) | EP0750668B1 (no) |
JP (2) | JP3822903B2 (no) |
AT (1) | ATE414152T1 (no) |
AU (1) | AU695208B2 (no) |
CA (1) | CA2185352C (no) |
DE (1) | DE69535883D1 (no) |
DK (1) | DK0750668T3 (no) |
FI (1) | FI120356B (no) |
NO (1) | NO318989B1 (no) |
NZ (2) | NZ329970A (no) |
WO (1) | WO1995025170A1 (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0948358B2 (en) * | 1996-12-24 | 2011-11-23 | Biogen Idec MA Inc. | Stable liquid interferon formulations |
PT1121156E (pt) | 1998-10-16 | 2006-05-31 | Biogen Idec Inc | Conjugados de polimeros de interferao-beta-1a e as suas utilizacoes |
DE69931507T2 (de) * | 1998-10-16 | 2007-01-11 | Biogen Idec Ma Inc., Cambridge | Interferon-beta fusionsproteine und deren verwendungen |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US7431921B2 (en) * | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
WO2001041782A2 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
ATE432288T1 (de) | 2001-02-27 | 2009-06-15 | Maxygen Aps | Neue interferon-beta-ähnliche moleküle |
WO2002072019A2 (en) * | 2001-03-13 | 2002-09-19 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
EP1435979A4 (en) * | 2001-09-18 | 2008-01-23 | Novartis Vaccines & Diagnostic | METHODS OF TREATING MULTIPLE SCLEROSIS |
ZA200700168B (en) | 2001-10-10 | 2010-02-24 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
AU2003263552A1 (en) | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004028472A2 (en) * | 2002-09-27 | 2004-04-08 | Biogen Idec Ma Inc. | THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
EP1581631A4 (en) * | 2002-10-01 | 2007-09-05 | Xencor Inc | INTERFERON VARIANTS HAVING IMPROVED PROPERTIES |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
NZ548255A (en) | 2004-02-02 | 2010-10-29 | Ambrx Inc | Modified human interferon polypeptides and their uses |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
EP1885858A2 (en) * | 2005-05-19 | 2008-02-13 | Bayer Schering Pharma Aktiengesellschaft | Treatment of disease using an improved regulated expression system |
US20070179113A1 (en) * | 2005-05-19 | 2007-08-02 | Schering Aktiengesellachaft | GM-CSF gene therapy for Crohn's disease using an improved regulated expression system |
EP1891224A1 (en) * | 2005-05-19 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Interferon-beta gene therapy using an improved, regulated expression system |
US20080076729A1 (en) * | 2005-05-19 | 2008-03-27 | Schering Aktiengesellachaft | Interferon-beta gene therapy using an improved, regulated expression system |
PT1917276T (pt) * | 2005-08-26 | 2018-06-11 | Ares Trading Sa | Processo para a preparação de interferão beta glicosilado |
US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
WO2008125222A2 (en) * | 2007-04-11 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | New modulation molecules for an improved regulated expression system |
WO2008134406A1 (en) * | 2007-04-25 | 2008-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Ischemia-induced neovascularization is enhanced by hcns-sc transplantation |
EP2076533B1 (en) * | 2007-05-02 | 2014-10-08 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US8273561B2 (en) * | 2007-10-05 | 2012-09-25 | Nuron Biotech, Inc. | High pressure treatment of aggregated interferons |
EP2379711B8 (en) * | 2008-12-23 | 2017-03-22 | BOCO Silicon Valley, Inc. | Target populations of oligodendrocyte precursor cells and methods of making and using same |
WO2019073315A1 (en) | 2017-10-09 | 2019-04-18 | Mansour Poorebrahim | ANALOGUE PEPTIDE OF INTERFERON-BETA |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR860001471B1 (ko) * | 1980-04-03 | 1986-09-26 | 비오겐 엔. 브이 | 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법 |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
IE56026B1 (en) * | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
GB8334102D0 (en) * | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
DE3683910D1 (de) * | 1986-09-05 | 1992-03-26 | Cetus Corp | Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate. |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
IL92124A (en) * | 1988-10-28 | 1996-10-31 | Sidney Pestka | Recombinant proteins modified to contain post-phosphorylation that do not occur in nature |
WO1993015609A1 (en) * | 1992-02-05 | 1993-08-19 | Thomas Jefferson University | Interferon gene therapy for the treatment of vascular disorders |
-
1994
- 1994-03-15 US US08/213,448 patent/US5545723A/en not_active Expired - Lifetime
-
1995
- 1995-03-13 AT AT95914045T patent/ATE414152T1/de not_active IP Right Cessation
- 1995-03-13 WO PCT/US1995/003206 patent/WO1995025170A1/en active Application Filing
- 1995-03-13 NZ NZ329970A patent/NZ329970A/xx not_active IP Right Cessation
- 1995-03-13 DE DE69535883T patent/DE69535883D1/de not_active Expired - Lifetime
- 1995-03-13 DK DK95914045T patent/DK0750668T3/da active
- 1995-03-13 AU AU21202/95A patent/AU695208B2/en not_active Expired
- 1995-03-13 NZ NZ283217A patent/NZ283217A/en not_active IP Right Cessation
- 1995-03-13 EP EP95914045A patent/EP0750668B1/en not_active Expired - Lifetime
- 1995-03-13 CA CA002185352A patent/CA2185352C/en not_active Expired - Lifetime
- 1995-03-13 JP JP52414595A patent/JP3822903B2/ja not_active Expired - Lifetime
-
1996
- 1996-09-13 NO NO19963837A patent/NO318989B1/no not_active IP Right Cessation
- 1996-09-13 FI FI963630A patent/FI120356B/fi not_active IP Right Cessation
-
1997
- 1997-08-18 US US08/912,768 patent/US6127332A/en not_active Expired - Lifetime
-
2006
- 2006-04-17 JP JP2006113870A patent/JP2006199711A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP3822903B2 (ja) | 2006-09-20 |
ATE414152T1 (de) | 2008-11-15 |
WO1995025170A1 (en) | 1995-09-21 |
US5545723A (en) | 1996-08-13 |
NZ283217A (en) | 1998-05-27 |
NO318989B1 (no) | 2005-05-30 |
DK0750668T3 (da) | 2009-03-02 |
FI120356B (fi) | 2009-09-30 |
AU695208B2 (en) | 1998-08-06 |
AU2120295A (en) | 1995-10-03 |
NZ329970A (en) | 2000-01-28 |
MX9604073A (es) | 1997-12-31 |
JP2006199711A (ja) | 2006-08-03 |
DE69535883D1 (de) | 2008-12-24 |
US6127332A (en) | 2000-10-03 |
FI963630A (fi) | 1996-09-13 |
FI963630A0 (fi) | 1996-09-13 |
JPH10500563A (ja) | 1998-01-20 |
EP0750668B1 (en) | 2008-11-12 |
EP0750668A1 (en) | 1997-01-02 |
CA2185352C (en) | 2005-02-22 |
NO963837L (no) | 1996-11-14 |
CA2185352A1 (en) | 1995-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963837L (no) | Nye muteiner av IFN- | |
DK75694A (da) | Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren | |
NO931141L (no) | Tnf-muteiner | |
WO1995025170B1 (en) | NOVEL MUTEINS OF IFN-$g(b) | |
EP0787802A3 (no) | ||
RU95115239A (ru) | Аналог эритропоэтина | |
ATE152172T1 (de) | Herstellung eines rekombinanten menschlichen interleukin-1-hemmers | |
SE9004010D0 (sv) | Viralt medel | |
WO2002074980A3 (en) | Muteins of hypoxia inducible factor alpha and methods of use thereof | |
KR870004143A (ko) | Dna서열, 재조합 dna분자 및 뮬레리안억제 물질류 폴리펩티드의 생산 방법 | |
ATE380866T1 (de) | Modulatoren des tnf-rezeptor-assoziierten faktors,deren herstellung und verwendungen | |
ATE131493T1 (de) | Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase | |
EP1323824A3 (en) | Use of human keratinocyte growth factor-2 for the preparation of pharmaceutical compositions | |
DE69233143D1 (de) | Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung | |
ATE82127T1 (de) | N-acetylglucosamin-zubereitungen zur buccalen anwendung. | |
DE69229862D1 (de) | Cysteinfreie il-6 mutanten | |
EA200100395A1 (ru) | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием | |
ATE100717T1 (de) | Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons. | |
IT1262545B (it) | Sistema di espressione per linee cellulari eucariotiche | |
CA2004202A1 (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
Goelz et al. | Muteins of IFN-beta | |
GR3025841T3 (en) | An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof | |
Yamaguchi et al. | A procedure for the purification of ferritin using Matrex Red A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |